Navigation Links
New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C
Date:12/3/2009

HOERSHOLM, Denmark and SAN DIEGO, California, December 3 /PRNewswire/ --

- SPC3649 Successfully Inhibits miR-122, a microRNA Important for Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatitis C Virus in the Bloodstream in Chimpanzees Chronically Infected With the Hepatitis C Virus

- SPC3649 Demonstrates Efficacy With No Evidence of Viral Resistance and No Serious Adverse Events in the Treated Animals - Signaling a Potential Benefit for Patients Who are Not Responsive to or Cannot Tolerate Current Standard of Care Therapies

- SPC3649 is the First microRNA-Targeted Drug to Enter Human Clinical Trials; Phase 1 Clinical Trials Ongoing

- Santaris Pharma A/S Proprietary Locked Nucleic Acid (LNA) Drug Platform Fundamental in Developing Effective RNA-Targeted Therapies With High Affinity, Target Specificity and Remarkable Potency for a Range of Diseases

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090921/360545 )

The World Health Organization estimates about 3% of the world's population has been infected with HCV and that some 170 million are chronic carriers at risk of developing liver cirrhosis and/or liver cancer[1]. Approximately 3-4 million Americans are chronically infected with an estimated 40,000 new infections per year[2]. In Europe, there are about 4 million carriers[3].

Santaris Pharma A/S, the first company to have advanced both mRNA and microRNA targeted drugs into clinical trials, is an international biopharmaceutical c
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014  Sage Analytics ( www.sageanalytics.com ), ... for the testing of marijuana potency and moisture ... Luminary™ Profiler, the industry,s first product suite capable ... cost-effective, portable unit. Designed from the ... the cannabis industry, the Luminary™ Profiler utilizes specially ...
(Date:12/19/2014)... 2014 Capnia, Inc. (NASDAQ: ... diagnostics based on its proprietary Sensalyze™ Technology Platform ... financial results for the third quarter and nine ... the completion of our initial public offering (IPO), ... recently initiated CoSense® commercial launch," said Anish Bhatnagar, ...
(Date:12/19/2014)... LEXINGTON, Ky. , Dec. 18, 2014 Baptist ... United States to receive full Atrial Fibrillation with ... Patient Care (SCPC). Atrial fibrillation is the most ... concern that in some cases can lead to stroke and ... the United States have atrial fibrillation and the ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... Medivation, Inc.,(Nasdaq: MDVN ) today announced new ... produce broad, clinically meaningful benefits in,Alzheimer,s disease patients ... novel mechanism of action. These data were presented ... at the 2008 Alzheimer,s Association,International Conference on Alzheimer,s ...
... Improvement in Cognitive Performance and Global Clinical Status in ... ... Forest Laboratories, Inc.,(NYSE: FRX ) presented today positive Phase ... the 2008,Alzheimer,s Association International Conference on Alzheimer,s Disease,(ICAD). The study evaluated ...
Cached Medicine Technology:Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease 2Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease 3Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease 4Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease 5Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease 6New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 2New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 3New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 4
(Date:12/19/2014)... Novellus Healthcare Communications, LLC announces ... Clinics™, an independent journal that provides practical information ... for patients inside the pharmacy and retail clinics. ... optimal access to quality care, Inside Patient Care: ... team treating and coordinating patient care in pharmacies ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 From November 24, ... teacher training for the year 2014 in its Goa ... this year. Through the Indian winters, from November to March, ... the beautiful beach of Arambol, Goa. The Goa training sessions ... previous intakes of yoga teacher training, the 10th intake is ...
(Date:12/19/2014)... December 19, 2014 Consilium Staffing, ... the AMSUS Society for Federal Health Professionals annual ... tenens industry to military and federal healthcare providers. ... National Veterans Small Business Engagement (NVSBE) conference last ... to be a vital solution in addressing our ...
(Date:12/19/2014)... News) -- The tragic death from "rat-bite fever" of a ... pet rodents, according to a report from the U.S. Centers ... rare but potentially fatal illness that should be considered in ... history of rodent exposure is reported," said a team led ... The case outlined in the report occurred in August ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue eye ... significantly reduce the risk of vision loss in patients ... British researchers led by David Garway-Heath, of the Moorfields ... tracked outcomes for more than 500 people newly diagnosed ... the disease and one of the leading causes of ...
Breaking Medicine News(10 mins):Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2
... N.J., July 23 The New Jersey,Hospital Association,s ... planning grant for $199,502 from the Robert Wood ... the quality of,healthcare in New Jersey., The ... months whether New,Jersey can be represented in RWJF,s ...
... Laura Kolkman, President,Mosaica Partners, a nationally recognized ... to serve as Chair of the Healthcare,Information ... (HIE) Steering Committee., The HIE Steering ... including providers, payers, vendors, consultants and life,sciences, ...
... is a central component of engaging in conversation, but people ... a social interaction. New research from Carnegie Mellon University sheds ... social difficulties in autism, and on the workings of these ... to the study, which is available on the Web site ...
... software has recently added advanced features like shared whiteboard, chat and screen ... only available for a high cost with paid services like Webex. Also ... you log into your home or office PC from anywhere on the ... ...
... from Napa Valley and North Coast Appellations is offering the first ... providing excellent value for the fine wine consumer and collector. ... ... 2008 -- Fairhope Vintners, a producer of classically styled wines from ...
... (ACCP) invites journalists from around the world to ... assembly, held October 25-30, in Philadelphia, PA. CHEST ... clinical chest medicine, including pulmonology, critical care, cardiology, ... address, session topics, special events, or Philadelphia tourism, ...
Cached Medicine News:Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2Health News:Autism's social struggles due to disrupted communication networks in brain 2Health News:How to Conduct Free Web Meetings and Remote Desktop? 2Health News:Fairhope Vintners Offers First Release of Classically Styled Napa Valley Cabernet Sauvignon Wines 2Health News:Fairhope Vintners Offers First Release of Classically Styled Napa Valley Cabernet Sauvignon Wines 3Health News:CHEST 2008 Philadelphia: Media registration open 2
... Constructed of optical steel base metal ... design provides enhanced durability. Includes adjustable non-slip ... 662S Metalite comes with custom fitted lead ... to the front lenses for increased scatter ...
... optical steel base metal ... with custom fitted lead ... a seal to the ... scatter radiation protection. Includes ...
... Properly manufactured radiation protective eyewear can ... high quality frames and materials offer the ... Our lenses are made of Schott RS-520 ... standards. Most Pulse Glasses are offered with ...
... Stylish and comfortable eye protection ... approximately 90% of scatter radiation. Our high ... protection and comfort with minimized weight. Our ... leaded) optics that meet all industry standards. ...
Medicine Products: